Content
Asston Pharmaceuticals shares had a weak debut on July 16, listing at ₹119 on BSE SME, 3.25% below the IPO price of ₹123. The ₹27.63 crore SME IPO, open from July 9–11, saw robust demand, getting subscribed 186.55 times by investors.
The IPO received bids for 27.85 crore shares against 14.93 lakh shares on offer. Retail investors subscribed 172.06 times, NIIs subscribed 353.14 times, while the QIB segment saw strong interest with a 85.76 times subscription, reflecting high investor enthusiasm across categories.
Asston Pharmaceuticals Limited, incorporated in 2019, is a pharmaceutical company specializing in global exports of healthcare products. Its portfolio includes tablets, capsules, syrups, and sachets across therapeutic areas like antibiotics, antifungals, and vitamins, operating through direct and contract manufacturing models.
Also Read: Brigade Hotel IPO: Check the latest GMP for Brigade Hotel Ventures IPO here
The objective of Asston Pharmaceuticals’ IPO is to raise funds for working capital requirements, support business expansion, meet general corporate purposes, and strengthen the company’s financial position. The proceeds will help enhance operational capabilities and support growth in the competitive pharmaceutical sector.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.


